Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects

Pharmacy World and Science

Volumn 29, Issue 3, 2007, Pages 190-198

  El Tantawy, Walid H ^a   Salem, Heba F ^b   Mohammed Safwat, Nirmeen A S ^c  

^a NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

^b Beni Suef University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Clinical investigation; Eggs; Fascioliasis; Pharmacokinetics; Triclabendazole sulfoxide

Indexed keywords

SULFONE; SULFOXIDE; TRICLABENDAZOLE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FASCIOLA; FASCIOLIASIS; FECES ANALYSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PARASITOSIS; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANIMALS; ANTHELMINTICS; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EGYPT; FASCIOLA; FASCIOLIASIS; FECES; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PARASITE EGG COUNT;

EID: 34249891617     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9069-8     Document Type: Article

References (25)

1. Laburte C, Mott KE, Hull R, Severne Y. Triclabendazole for fascioliasis: efficacy and tolerability of a single treatment. Infectious diseases and public health. A research and clinical update. In: Angelico M, Rocchi G, editors. Italy: Balaban Publishers; p. 325-333.
2. Lecaillon JB, Godbillon J, Campestrini J, Naquira C, Miranda L, Pacheco R, Mull R Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998; 45:601-4.
3. Keiser J, Engels D, Büscher G, Utzinger J Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14(12):1513-26.
4. El-Shazly A, El-Desouky I, El-Feky A A case of ectopic fascioliasis in a farmer from Mansoura City. Dakahlia, Egypt. J Egypt Soc Parasitol 1991; 21:333-5.
5. Haseeb AN, El-Shazly AM, Arafa MA, Morsy AT A review on Fascioliasis in Egypt. J Egypt Soc Parasitol 2002; 32(1):317-54.
6. Robert W, Tolan RW Fascioliasis, http://www.emedicine.com/ped/topic760. htm. Cited 14-5-2006
7. Fairweather I Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol 2005; 79(3):227-34.
8. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of long - term low - level intraruminal administration of triclabendazole in buffalo with induced fasciolosis. Vet Res Commun 1996; 20:461-8.
9. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of long-term low- level intraruminal administration of triclabendazole in urea molasses blocks against induced bovine and bubaline fascioliasis. Vet Parasitol 1998; 76(8):57-64.
10. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Vet Parasitol 1996; 63(1-2):75-82.
11. Sanyal PK Pharmacokinetic behaviour of triclabendazole in domestic Ruminants follows single and divided dose administration. J Vet Parasitol 1998; 12(2):89-93.
12. Boray JC, Crowfoot PD, Strong MB, Allison JR, Schelenbaum M, Von Ornelli M, et al. Treatment of immature and mature Fasciola Hepatica infections in sheep and cattle. Vet Rec 1983; 113:315-7.
13. Negro A, Alvarez-Bujidos ML, Ortiz AI, Cubria JC, Menedez R, Ordonez D Reversed - phase ion - pair high performance liquid chromatographic determination of triclabendazole metabolites in serum and urine. J Chromatogr 1992; 576:135-141.
14. Martin LK, Beaver PC Evaluation of Kato-Katz thick smear technique for quantitative diagnosis of helminthes infection. Am J Trop Med Hyg 1968; 17:382.
15. Hennessy DR, Lacey E, Steel JW, Prichard RK The kinetics of triclabendazole disposition in sheep. J Vet Pharmacol Ther 1987; 10(1):64-72.
16. Alvinerie M, Galter P Assay of triclabendazole and its main metabolites in plasma by high performance liquid chromatography. J Chromatogr 1986; 374:409-414.
17. Abd Elbary A, Foda N, El-Gazayerly O, El Khatib M Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal Letters 2002; 35(6):1041-54.
18. Lancaster R 1980 Pharmacology in clinical practice. Butterworth - Williams Heinenmann Medical books Ltd, London (UK), p. 44. ISBN 0433190523.
19. Chen MG, Mott KE Progress in assessment of morbidity due to Fasciola Hepatica infection: a review of recent literature. Trop Dis Bull 1990; 87:1-26.
20. Kinabo LDB, Bogan JA Pharmacokinetics and efficacy of triclabendazole in goats with induced fasciolosis. J Vet Pharmacol Ther 1988; 11:254-59.
21. Yadegari D, Talaie H, Massoud J Clinical trial of triclabendazole on human fascioliasis: long term follow-up. Med J Islam Rep Iran 1999; 13:89-91.
22. Farid Z, Trabbolsi B, Boctor F, Hafez A Unsuccessful use of praziquantel to treat fascioliasis in children. J Infect Dis 1986; 154:920-921.
23. Farid Z, Kamal M, Waodly J Treatment of acute toxaemic fascioliasis. Trans R Soc Trop Med Hyg 1988; 82:299.
24. Farid Z, Kamal M, Mansour N Praziquantel and Fasciola Hepatica infection. Trans R Soc Trop Med Hyg 1989; 83:813.
25. Apt W, Aguilera X, Vega F, Miranda C, Zulantay I, Perez C, Gabor M, Apt P Treatment of human chronic fasciolosis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52(6):532-5.